Professor Greg Goodall

Prof Gregory Goodall

Prof Gregory Goodall is head of the Gene Regulation Laboratory at the Centre for Cancer Biology, Adelaide. His research revolves around the roles that microRNAs play in cancer metastasis. His group was among the first to construct and use microRNA microarrays, which in collaboration with the EMT group of Dr. Yeesim Khew-Goodall lead to the landmark discovery of a microRNA family that controls EMT, with important implications for tumour metastasis. Their report in Nature Cell Biol (2008) is the most highly cited of all papers on microRNAs in cancer. Prof Goodall has been a Postdoctoral Fellow of the Roche Institute of Molecular Biology, NJ, Research Fellow at Cornell University Medical School, NY and at the Friedrich Miescher Institute, Basel, Switzerland. He is currently chief investigator of the NBCF EMPathy Project Target Discovery theme, a chief investigator on 6 NHMRC grants and is an NHMRC senior research fellow. He serves on the editorial board of the journal Oncogene. He has served on the National Cancer Research Grants Specialty Committee 2001-2004, Cancer Council of SA Cancer Research Advisory Committee 2001-2003, Australian Cancer Research Foundation DNA Resources Committee, 2001-2004, NHMRC Grant Review Panels 2000, 2006-2008, 2011. He was chair of the organising committee for the 2011 Barossa Science Among the Vines and is chair of the program committee for the Combio 2012 conference. He is director of the ACRF SA Cancer Genome Research Facility.

Prof Goodall leads the Target Discovery stream of the EMPathy network. He and his group, along with Prof Thompson and various satellite investigators, will apply various discovery approaches to identify genes that affect EMT, invasion and metastasis, providing numerous candidates for assessment in the mechanism and pre-clinical themes for their potential as diagnostic or therapeutic targets.

Key Achievements and Awards

  • Discovered further links between miR-200, ZEB transcription repressors and TGF-β in control of EMT.
  • Used mouse cancer models to determine effects of miR-200 on cancer metastasis.
  • Has developed genome wide methods for identifying microRNA targets in cancer cells.